The first and only automated, on-demand assay for the measurement of ADAMTS13 Activity, this assay measures the only biomarker specific for TTP, a life-threatening, hematologic disease.Ģ020 has been marked by the monumental challenge of COVID-19. For use on the ACL AcuStar® Hemostasis Testing System, this fully automated, chemiluminescent immunoassay offers clinicians rapid, on-demand ADAMTS13 activity testing to aid in the diagnosis and monitoring of Thrombotic Thrombocytopenia Purpura (TTP), with first results produced in approximately 30 minutes. Initially released in the United Kingdom, the system was commercialized in the US in early 2020.Īdditionally in 2019, IL commercialized the HemosIL® AcuStar ADAMTS13 Activity assay in the European Union and other international markets. Providing laboratory-quality results on-demand, in less than 70 seconds, from venous or arterial lithium-heparinized, whole-blood samples, the system aids in the timely triage and management of high-risk, acutely ill patients. In 2019, the Company released the new GEM Premier ChemSTAT™ analyzer with Intelligent Quality Management (iQM®) for rapid basic metabolic panel (BMP) testing at the point of care, primarily in hospital Emergency Departments and Clinical Laboratories. We thank them for their countless hours and dedication to critical patient care and, we acknowledge our employees, who have met increased product demand and helped maintain customer operations during this most challenging time.' First in China, and then worldwide, our customers rely on IL to help manage patients hospitalized with COVID-19. 'This trust, and our responsibility to earn it every day, has never been more evident. Our worldwide sales continued their rapid growth, underscoring the trust our customers place in IL products and services,' said Ramon Benet, CEO at IL. '2019 marked our 60 th anniversary of passion and results, and was another excellent year for innovation and new product development. By product line, the Company's Patient Blood Management and Whole Blood Hemostasis lines performed particularly well, with 20.9% and 10.4% growth, respectively. In the Hemostasis business line, sales grew 6.5% in local currencies, solidifying the Company's global leadership position. All key territories contributed, led by China with 15.6% and North America, 7.9%. In the Acute Care Diagnostics business line, sales grew 8.9% in local currencies. All key territories contributed to growth, including China with 11.3%, Latin America, 11.3%, and the US, 10.6%. IL, an integral part of Werfen, specializes in Acute Care and Hemostasis in vitro diagnostic solutions for clinical laboratories and hospital acute-care settings. BEDFORD, Mass., /PRNewswire/ - Instrumentation Laboratory (IL) today announced total worldwide sales in 2019 of $1,096 M (€978 M), with total growth of 7.6% over 2018, in local currencies.

Instrumentation laboratory